To study the pharmacokinetic properties of recombinant human interleukin-11 injection of Xiamen Tebao Biotechnology Co., Ltd. in healthy male subjects after a single dose, and use its lyophilized powder injection as a reference to evaluate the bioequivalence of the test drug and the reference drug, so as to provide a basis for safe and rational clinical drug use and to increase the injection dosage form.

Start Date30 Oct 2013

Sponsor / Collaborator

Xiamen Amoytop Biotech Co. Ltd.

ChiCTR-TNC-10000758 / CompletedPhase 4IIT

The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC Receiving Gemcitabine and Cisplatin or Carboplatin Chemotherapy

Start Date01 Feb 2010

Sponsor / Collaborator

Shanghai Chest Hospital

100 Clinical Results associated with Recombinant human interleukin-11(Xiamen Amoytop Biotech Co. Ltd.)

100 Translational Medicine associated with Recombinant human interleukin-11(Xiamen Amoytop Biotech Co. Ltd.)

100 Patents (Medical) associated with Recombinant human interleukin-11(Xiamen Amoytop Biotech Co. Ltd.)

325

Literatures (Medical) associated with Recombinant human interleukin-11(Xiamen Amoytop Biotech Co. Ltd.)

15 Apr 2024·Cancer

A real‐world observation on thrombopoietic agents for patients with cancer treatment–induced thrombocytopenia in China: A multicenter, cross‐sectional study

Article

Author: Wang, Huaqing ; Ba, Yi ; Qian, Liting ; Yuan, Xianglin ; Wang, Wei ; Zhang, Yanqiao ; Shu, Yongqian ; Xue, Cong ; Zhou, Min ; Liu, Tianshu ; Li, Xiaoling ; Cheng, Jing ; Liao, Zijun ; Gu, Kangsheng ; Zhang, Qingyuan ; Wang, Chang ; Hou, Mei ; Qiu, Wensheng ; Chen, Xi ; Zhong, Jincai ; Xu, Ruilian ; Feng, Jifeng ; Yang, Runxiang ; Zhang, Mingzhi ; Xia, Qing ; Li, Enxiao ; Liao, Wangjun ; Chen, Xiaobing ; Chen, Meiting ; Wang, Xiaojia ; An, Xin ; Chen, Yu ; Li, Lu ; Shen, Bo ; Ma, Fei ; Yang, Nong ; Deng, Ting ; Wang, Zhehai ; Liu, Bin ; Shi, Yanxia

AbstractBackgroundStudies on various thrombopoietic agents for cancer treatment–induced thrombocytopenia (CTIT) in China are lacking. This study aimed to provide detailed clinical profiles to understand the outcomes and safety of different CTIT treatment regimens.MethodsIn this retrospective, cross‐sectional study, 1664 questionnaires were collected from 33 hospitals between March 1 and July 1, 2021. Patients aged >18 years were enrolled who were diagnosed with CTIT and treated with recombinant interleukin 11 (rhIL‐11), recombinant thrombopoietin (rhTPO), or a thrombopoietin receptor agonist (TPO‐RA). The outcomes, compliance, and safety of different treatments were analyzed.ResultsAmong the 1437 analyzable cases, most patients were treated with either rhTPO alone (49.3%) or rhIL‐11 alone (27.0%). The most common combination regimen used was rhTPO and rhIL‐11 (10.9%). Platelet transfusions were received by 117 cases (8.1%). In multivariate analysis, rhTPO was associated with a significantly lower proportion of platelet recovery, platelet transfusion, and hospitalization due to chemotherapy‐induced thrombocytopenia (CIT) than rhIL‐11 alone. No significant difference was observed in the time taken to achieve a platelet count of >100 × 109/L and chemotherapy dose reduction due to CIT among the different thrombopoietic agents. The outcomes of thrombocytopenia in 170 patients who received targeted therapy and/or immunotherapy are also summarized. The results show that the proportion of platelet recovery was similar among the different thrombopoietic agents. No new safety signals related to thrombopoietic agents were observed in this study. A higher proportion of physicians preferred to continue treatment with TPO‐RA alone than with rhTPO and rhIL‐11.ConclusionsThis survey provides an overview of CTIT and the application of various thrombopoietic agents throughout China. Comparison of monotherapy with rhIL‐11, rhTPO, and TPO‐RA requires further randomized clinical trials. The appropriate application for thrombopoietic agents should depend on the pretreatment of platelets, treatment variables, and risk of bleeding.Plain Language Summary

To provide an overview of the outcome of cancer treatment–induced thrombocytopenia in China, our cross‐sectional study analyzed 1437 cases treated with different thrombopoietic agents.

Most of the patients were treated with recombinant interleukin 11 (rhIL‐11) and recombinant thrombopoietin (rhTPO).

rhTPO was associated with a significantly lower proportion of platelet recovery and platelet transfusion compared with rhIL‐11.

01 Nov 2023·Pharmacological Research

Targeting IL-11 system as a treatment of pulmonary arterial hypertension

Article

Author: Milara, Javier ; Escrivá, Juan ; Montero, Paula ; Roger, Inés ; Artigues, Enrique ; Cortijo, Julio ; Perez-Vizcaino, Francisco

IL-11 is linked to fibrotic diseases, but its role in pulmonary hypertension is unclear. We examined IL-11's involvement in idiopathic pulmonary arterial hypertension (iPAH). Using samples from control (n = 20) and iPAH (n = 6) subjects, we assessed IL-11 and IL-11Rα expression and localization through RT-qPCR, ELISA, immunohistochemistry, and immunofluorescence. A monocrotaline-induced PAH model helped evaluate the impact of siRNA-IL-11 on pulmonary artery remodeling and PH. The effects of recombinant human IL-11 and IL-11Rα on human pulmonary artery smooth muscle cell (HPASMC) proliferation, pulmonary artery endothelial cell (HPAEC) mesenchymal transition, monocyte interactions, endothelial tube formation, and precision cut lung slice (PCLS) pulmonary artery remodeling and contraction were evaluated. IL-11 and IL-11Rα were over-expressed in pulmonary arteries (3.2-fold and 75-fold respectively) and serum (1.5-fold and 2-fold respectively) of patients with iPAH. Therapeutic transient transfection with siRNA targeting IL-11 resulted in a significant reduction in pulmonary artery remodeling (by 98%), right heart hypertrophy (by 66%), and pulmonary hypertension (by 58%) in rats exposed to monocrotaline treatment. rhIL-11 and soluble rhIL-11Rα induce HPASMC proliferation and HPAEC to monocyte interactions, mesenchymal transition, and tube formation. Neutralizing monoclonal IL-11 and IL-11Rα antibodies inhibited TGFβ1 and EDN-1 induced HPAEC to mesenchymal transition and HPASMC proliferation. In 3D PCLS, rhIL-11 and soluble rhIL-11Rα do not promote pulmonary artery contraction but sensitize PCLS pulmonary artery contraction induced by EDN-1. In summary, IL-11 and IL-11Rα are more highly expressed in the pulmonary arteries of iPAH patients and contribute to pulmonary artery remodeling and the development of PH.

01 Feb 2023·Journal of Stroke and Cerebrovascular Diseases

Anti-apoptosis effect of recombinant human interleukin-11 in neonatal hypoxic-ischemic rats through activating the IL-11Rα/STAT3 signaling pathway

Article

Author: Xiong, Ying ; Xiao, Mei ; Zhang, Qing ; Wang, Xiaoya ; Chen, Huixin ; Feng, Zhanhui ; Ye, Lan ; Zuo, Ding ; Zheng, Qian ; Xu, Jianwei

Hypoxia-ischemia (HI) is one of the most common causes of death and disability in neonates. Apoptosis contributes to HI development. Interleukin-11(IL-11) has been shown to protect mice from cerebral ischemia/reperfusion injury. However, whether IL-11 exerts the anti-apoptotic effect on HI injury is unclear. In this study, we demonstrated that recombinant human IL-11 (rhIL-11) prevented apoptosis of rat neonates with HI through activating IL-11Rα/STAT3 signaling. Sprague-Dawley rat pups on the 7th day after birth were used to establish an HI injury model. The expression levels of IL-11Rα and GP130 were increased first and then decreased after HI. In contrast, IL-11 expression was first decreased and then increased. Immunofluorescence staining showed that IL-11Rα was localized in neurons and oligodendrocytes. RhIL-11 treatment alleviated hippocampal and cortical damages, significantly reduced cerebral infarction volumes, cerebral edema, and loss of the Nissl body and nerve cells, and also ameliorated the outcomes of HI injury and long-term neurological deficits. In addition, rhIL-11 treatment upregulated the expressions levels of Bcl-2 and p-STAT3/STAT3, and downregulated the protein concentrations of the lytic protease, and cleaved-caspase-3. Furthermore, GP130 inhibitor and JAK1 inhibitor reversed the protective effects of rhIL-11. Overall, rhIL-11 showed an anti-apoptosis effect on the brain after HI injury. Our results indicated that rhIL-11 reduced neuronal apoptosis by activating the brain IL-11Rα/STAT3 pathway.

100 Deals associated with Recombinant human interleukin-11(Xiamen Amoytop Biotech Co. Ltd.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AC02	DB00038

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Leukopenia	CN	Xiamen Amoytop Biotech Co. Ltd.	11 Apr 2005
Solid tumor	CN	Xiamen Amoytop Biotech Co. Ltd.	11 Apr 2005
Thrombocytopenia	CN	Xiamen Amoytop Biotech Co. Ltd.	11 Apr 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis